Metreleptin
Also called Myalept
Subcutaneous (under the skin)Product label
Research reference
Product label
Myalept individualized daily schedule
Once daily; starting amount depends on body weight and, above 40 kg, sex
Ongoing clinical and metabolic review; not a fixed wellness cycle
Myalept product label ↗When results may show
- When change was measured
- Glucose, triglycerides, antibodies and the underlying condition require specialist monitoring. Insulin may need adjustment.
- When to assess
- Ongoing clinical and metabolic review; not a fixed wellness cycle
- Conditions and limitations
- Generalized lipodystrophy with leptin deficiency; not ordinary obesity. The restricted-access product and its supplied instructions matter. Its daily dose and product-specific reconstitution cannot be generalized to leptin vials.
- When to stop
- Use the exact product's clinical monitoring and stopping instructions. A supply interval is not a stop date; severe or persistent reactions need prompt clinical review.
Sources: Myalept product label
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Metreleptin describe 2.5–10 mg per administration. Descriptive only, not a recommendation.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.02× single dose
- Time to steady state
- 20hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Myalept product labelThe restricted-access product and its supplied instructions matter. Its daily dose and product-specific reconstitution cannot be generalized to leptin vials.
Next steps
Metreleptin beginner guideOpen Metreleptin planning worksheetEstimate Metreleptin vial costTrack Metreleptin notes